Information gathered in this review could provide a guideline for the direction in which the research of NAFLD-HCC pathophysiology should be directed to uncover the molecular mechanisms underlying LCN2 activity and making its use as a biomarker routinely available. The gene discussed is LCN2; the disease is metabolic dysfunction-associated steatotic liver disease.